Cancer-Associated Myositis and Anti-p155 Autoantibody in a Series of 85 Patients With Idiopathic Inflammatory Myopathy

Trallero-Araguás, Ernesto; Labrador‐Horrillo, Moisés; Selva-O’Callaghan, Albert; Martínez, María Ángeles; Martínez‐Gómez, Xavier; Palou, Eduard; Rodríguez-Sánchez, José L.; Vilardell‐Tarrés, Miquel

doi:10.1097/md.0b013e3181ca14ff

Cited by 81 publications

(81 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, one study reported that the performance of FDG-PET/CT for diagnosing cancer in patients with myositis (DM and PM) was comparable to that of broad conventional screening [39]. Also, antibodies to transcription intermediary factor-1c (antip155, anti-155/140, anti-p155/140) have been associated with cancer in adult patients with DM [41][42][43][44][45][46]. Nevertheless, the usefulness of these autoantibodies for cancer screening patients with myositis remains to be elucidated.…”

Section: Discussionmentioning

confidence: 96%

Cancer Risk in Dermatomyositis: A Meta-Analysis of Cohort Studies

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Cancer Risk in Dermatomyositis: A Meta-Analysis of Cohort Studies

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In individuals with cancer, a mutation of p53 may lead to the development of cancer while the mutated p53 is recognized as non-self by the immune system and trigger autoantibodies to p53. Autoantibodies to p155/140 (transcription intermediary factor-1γ, TIF-1γ) have been described recently in strong association with cancer-associated DM [57][58][59][60]. Based on the tumor-suppressive effects of TIF-1γ described in murine models and human [61][62][63], it seems reasonable to hypothesize that TIF-1γ mutation is the primary event that leads to Fig.…”

Section: Mechanisms Of Myositis Autoantibody Production and Pathogenementioning

confidence: 96%

Common Pathways of Autoimmune Inflammatory Myopathies and Genetic Neuromuscular Disorders

Satoh

Ceribelli

Chan

2011

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

It has been shown that many hereditary motor neuron diseases are caused by mutation of RNA processing enzymes. Survival of motor neuron 1 (SMN1) is well-known as a causative gene for spinal muscular atrophy (SMA) and mutations of glycyl- and tyrosyl-tRNA synthetases are identified as a cause of distal SMA and Charcot-Marie-Tooth disease. Why and how the dysfunction of these ubiquitously expressed genes involved in RNA processing can cause a specific neurological disorder is not well understood. Interestingly, SMN complex has been identified recently as a new target of autoantibodies in polymyositis (PM). Autoantibodies in systemic rheumatic diseases are clinically useful biomarkers associated with a particular diagnosis, subset of a disease, or certain clinical characteristics. Many autoantibodies produced in patients with polymyositis/dermatomyositis (PM/DM) target RNA-protein complexes such as aminoacyl tRNA synthetases. It is interesting to note these same RNA-protein complexes recognized by autoantibodies in PM/DM are also responsible for genetic neuromuscular disease. Certain RNA-protein complexes are also targets of autoantibodies in paraneoplastic neurological disorders. Thus, there are several interesting associations between RNA-processing enzymes and neuromuscular disorders. Although pathogenetic roles of autoantibodies to intracellular antigens are generally considered unlikely, understanding the mechanisms of antigen selection in a particular disease and specific neurological symptoms caused by disruption of ubiquitous RNA-processing enzyme may help identify a common path in genetic neuromuscular disorders and autoimmunity in inflammatory myopathies.

show abstract

“…Over the last few years, it is now evident that cancer-associated DM is an antibody-rich rheumatic phenotype with the discovery of anti-TIF1 and more recently anti-NXP2 autoAb. Anti-TIF1 has now been described in around 15-25 % of DM cohort studies [57][58][59][60]. The identity of the 155/ 140 kDa protein was subsequently identified as the TIF1 (α, β, γ subunits) family proteins, with TIF1-γ the main target [60].…”

Section: Anti-tif1 and Anti-nxp2 Autoabmentioning

confidence: 99%

The Clinical Features of Myositis-Associated Autoantibodies: a Review

Gunawardena

2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

The idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases traditionally defined by clinical manifestations including skeletal muscle weakness, skin rashes, elevated skeletal muscle enzymes, and neurophysiological and/or histological evidence of muscle inflammation. Patients with myositis overlap can develop other features including parenchymal lung disease, inflammatory arthritis, gastrointestinal manifestations and marked constitutional symptoms. Although patients may be diagnosed as having polymyositis (PM) or dermatomyositis (DM) under the IIM spectrum, it is quite clear that disease course between subgroups of patients is different. For example, interstitial lung disease may predominate in some, whereas cutaneous complications, cancer risk, or severe refractory myopathy may be a significant feature in others. Therefore, tools that facilitate diagnosis and indicate which patients require more detailed investigation for disease complications are invaluable in clinical practice. The expanding field of autoantibodies (autoAbs) associated with connective tissue disease (CTD)-myositis overlap has generated considerable interest over the last few years. Using an immunological diagnostic approach, this group of heterogeneous conditions can be separated into a number of distinct clinical phenotypes. Rather than diagnose a patient as simply having PM, DM or overlap CTD, we can define syndromes to differentiate disease subsets that emphasise clinical outcomes and guide management. There are now over 15 CTD-myositis overlap autoAbs found in patients with a range of clinical manifestations including interstitial pneumonia, cutaneous disease, cancer-associated myositis and autoimmune-mediated necrotising myopathy. This review describes their diagnostic utility, potential role in disease monitoring and response to treatment. In the future, routine use of these autoAb will allow a stratified approach to managing this complex set of conditions.

show abstract

Cancer-Associated Myositis and Anti-p155 Autoantibody in a Series of 85 Patients With Idiopathic Inflammatory Myopathy

Cited by 81 publications

References 24 publications

Cancer Risk in Dermatomyositis: A Meta-Analysis of Cohort Studies

Cancer Risk in Dermatomyositis: A Meta-Analysis of Cohort Studies

Common Pathways of Autoimmune Inflammatory Myopathies and Genetic Neuromuscular Disorders

The Clinical Features of Myositis-Associated Autoantibodies: a Review

Contact Info

Product

Resources

About